Cvs Health (CVS) EBIT (2009 - 2026)

Cvs Health (CVS) has reported EBIT for 18 consecutive years, with $4.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 97.52% year-over-year to $4.7 billion; the trailing twelve-month figure through Jun 2026 stood at $8.3 billion (down 7.45% YoY), and the FY2025 full-year result was $4.7 billion, down 45.28% from the prior year.
• EBIT was little changed at $4.7 billion in Q2 2026 per CVS's latest filing, from $4.7 billion in the prior quarter.
• Across five years, EBIT topped out at $4.7 billion in Q2 2026 and bottomed at -$3.9 billion in Q3 2022.
• Historically, EBIT has averaged $2.5 billion across 5 years, with a median of $3.3 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 194.16% in 2023, then slumped 485.46% in 2025.
• Over 5 years, EBIT stood at $3.7 billion in 2022, then fell by 7.82% to $3.4 billion in 2023, then dropped by 29.8% to $2.4 billion in 2024, then decreased by 10.81% to $2.1 billion in 2025, then surged by 122.68% to $4.7 billion in 2026.
• According to Business Quant data, EBIT over the past three periods registered $4.7 billion, $4.7 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.